Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

The market is projected to reach $110.61 billion by 2030, growing at a 38.6% clip from 2025, as ROI-focused tools displace experimental pilots ( [3]) . With nearly 40% of hospitals now operating at ...

If confirmed, the safety review could herald the imposition of restrictions on the use of the antibodies by HHS, which has ...

Kymera Therapeutics, Inc. KYMR recently announced that the FDA granted Fast Track designation to pipeline candidate KT-621 ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Our picks for lesser-known uses for FSA money, from wearable tech to skin care to breastfeeding supplies.

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

Hims reports that 70% of Americans believe an economic downturn encourages healthier habits, like cooking at home and ...

The prior authorization bundles are for condition-specific procedures, Aetna said. Previously, providers had to submit two ...